Scarica l'app Stockscreener
59.08
0.22%
0.13
Dopo l'orario di chiusura:
59.14
0.06
+0.10%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BMY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Bristol Myers Squibb Co Borsa (BMY) Ultime notizie
Want Decades of Passive Income? Buy This Index Fund and Hold It Forever - The Motley Fool
Bristol Myers Squibb to make immune cell cancer therapies in Japan - Nikkei Asia
Bristol Myers Squibb Co. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Bristol-Myers Squibb Co. (NYSE:BMY): A High-Yield Dividend Stock for Income Investors - ChartMill
Bristol Myers Squibb Company $BMY Shares Sold by Employees Retirement System of Texas - MarketBeat
Colgate-Palmolive Elects Christopher Boerner, Ph.D. to Board of Directors - citybiz
Colgate-Palmolive raises dividend, adds Bristol Myers CEO to board By Investing.com - Investing.com India
Is Bristol Myers' Deep Pipeline the Key to Future Growth? - The Globe and Mail
Piper Sandler Sees Path to Growth for Bristol-Myers Squibb Company (BMY) After Eliquis Patent Expiry - Insider Monkey
UBS Boosts Bristol-Myers Squibb (BMY) Price Target as Milvexian Data Looms - Finviz
LGT Fund Management Co Ltd. Has $372,000 Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol-Myers Squibb Readies New Growth Drivers In Immunology And Cancer - simplywall.st
Bristol Myers Squibb (NYSE:BMY) Boosts Research Strengthening S&P 500 Index Momentum - Kalkine Media
BMY Wins FDA Nod to Expand Sotyktu Label for Psoriatic Arthritis - Finviz
Bristol Myers Squibb reports positive phase 3 trial results - Investing.com
Bristol's cancer treatment meets main goal in late-stage trial - AOL.com
Bristol's drug enhances survival rates in late-stage blood cancer trial - Reuters
New Bristol Myers pill delays myeloma progression in key late-stage trial - Stock Titan
Blair William & Co. IL Reduces Bristol Myers Squibb Stake - National Today
Oral Mucositis Market Set to Boom Through 2033 | Bristol-Myers Squibb • Pfizer Inc. • Novartis AG - openPR.com
Pitcairn Co. Sells 20,260 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
B. Metzler seel. Sohn & Co. AG Has $5.05 Million Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers (BMY) Gains FDA Approval for Sotyktu in Psoriatic Arthritis Treatment - GuruFocus
Munich Reinsurance Co Stock Corp in Munich Takes $2.78 Million Position in Bristol Myers Squibb Company $BMY - MarketBeat
Grantham Mayo Van Otterloo & Co. LLC Has $43.66 Million Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb's Sotyktu Approved for Psoriatic Arthritis Treatment - Intellectia AI
Bristol Myers Wins FDA Approval for Sotyktu for Psoriatic Arthritis - Benzinga
Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors - MSN
Bristol Myers wins FDA nod to expand Sotyktu label (BMY:NYSE) - Seeking Alpha
Painful psoriatic arthritis gets new oral option with FDA Sotyktu approval - Stock Titan
UBS raises Bristol-Myers Squibb stock price target on pipeline outlook - Investing.com
Why Bristol-Myers Squibb Remains a Top Healthcare Dividend Stock Pick - Tokenist
IFG Advisory LLC Acquires New Position in Bristol Myers Squibb Company - National Today
Edgar Lomax Co. VA Reduces Stock Holdings in Bristol Myers Squibb Company $BMY - MarketBeat
Is It Too Late To Consider Bristol Myers Squibb (BMY) After Recent Share Price Strength? - simplywall.st
Bristol-Myers Squibb Announces Cash Tender Offer For Up to $750 Million Aggregate Principal Amount of its Outstanding Debt Se... - mx.advfn.com
Can Reblozyl Stabilize BMY's Top Line Amid Legacy Drugs Decline? - TradingView
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
Assessing Bristol Myers Squibb (BMY) Valuation After Recent Share Price Momentum And 2024 Results - simplywall.st
Bristol Myers Squibb Awaits FDA Verdict On Sotyktu In Psoriatic Arthritis - RTTNews
Q4 Earnings Outperformers: Bristol-Myers Squibb (NYSE:BMY) And The Rest Of The Branded Pharmaceuticals Stocks - Finviz
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors - MarketWatch
How New Oncology Wins and a Fresh Dividend At Bristol Myers Squibb (BMY) Have Changed Its Investment Story - simplywall.st
Wealthedge Investment Advisors Boosts Bristol Myers Squibb Holdings - National Today
Bristol Myers Squibb declares $0.63 quarterly dividend - Investing.com
APG Asset Management Trims Bristol Myers Squibb Stake - National Today
Elo Mutual Pension Insurance Co Increases Bristol Myers Squibb Position - National Today
Bristol-Myers Squibb (BMY) Maintains Quarterly Dividend of $0.63/Share - GuruFocus
Bristol Myers Squibb at TD Cowen Conference: Strategic Growth Amid Challenges - Investing.com
BMY Gains 11.4% in a Month: Should You Buy, Sell or Hold the Stock? - TradingView
Evinova and Bristol Myers Squibb Collaborate to Advance AI-Driven Clinical Development - The Healthcare Technology Report.
Elo Mutual Pension Insurance Co Has $13.63 Million Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
What Bristol-Myers Squibb (BMY)'s Triple-Negative Breast Cancer Phase III Survival Win Means For Shareholders - Yahoo Finance
Bristol-Myers Squibb Cancer Advances Test Valuation Gap For Investors - simplywall.st
Is Bristol Myers Squibb (BMY) Pricing Look Attractive After Recent Share Price Climb - Yahoo Finance
Intech Investment Management Reduces Stake in Bristol Myers Squibb - National Today
Bristol-Myers Campus Sale Suit Sent Back To NJ - Law360
US Bancorp DE Trims Bristol Myers Squibb Stake - National Today
1.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):